RU2013154699A - Сцилло-инозитол для применения в лечении поведенческих и психических расстройств - Google Patents
Сцилло-инозитол для применения в лечении поведенческих и психических расстройств Download PDFInfo
- Publication number
- RU2013154699A RU2013154699A RU2013154699/15A RU2013154699A RU2013154699A RU 2013154699 A RU2013154699 A RU 2013154699A RU 2013154699/15 A RU2013154699/15 A RU 2013154699/15A RU 2013154699 A RU2013154699 A RU 2013154699A RU 2013154699 A RU2013154699 A RU 2013154699A
- Authority
- RU
- Russia
- Prior art keywords
- inositol
- dementia
- scylo
- patient
- therapeutically effective
- Prior art date
Links
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 title claims abstract 11
- 230000003542 behavioural effect Effects 0.000 title 1
- 230000003236 psychic effect Effects 0.000 title 1
- CDAISMWEOUEBRE-CDRYSYESSA-N scyllo-inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O CDAISMWEOUEBRE-CDRYSYESSA-N 0.000 title 1
- 229960000367 inositol Drugs 0.000 claims abstract 42
- 238000000034 method Methods 0.000 claims abstract 35
- 206010012289 Dementia Diseases 0.000 claims abstract 23
- 208000024891 symptom Diseases 0.000 claims abstract 20
- 208000024827 Alzheimer disease Diseases 0.000 claims abstract 12
- 210000004556 brain Anatomy 0.000 claims abstract 10
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 claims abstract 10
- 201000011240 Frontotemporal dementia Diseases 0.000 claims abstract 5
- 230000001934 delay Effects 0.000 claims abstract 4
- 208000020925 Bipolar disease Diseases 0.000 claims abstract 3
- 208000010877 cognitive disease Diseases 0.000 claims abstract 3
- 208000027061 mild cognitive impairment Diseases 0.000 claims abstract 3
- 201000010374 Down Syndrome Diseases 0.000 claims 4
- 201000004810 Vascular dementia Diseases 0.000 claims 4
- 206010002942 Apathy Diseases 0.000 claims 3
- 206010013142 Disinhibition Diseases 0.000 claims 3
- 230000003247 decreasing effect Effects 0.000 claims 3
- 208000019901 Anxiety disease Diseases 0.000 claims 2
- 206010012218 Delirium Diseases 0.000 claims 2
- 208000004547 Hallucinations Diseases 0.000 claims 2
- 238000013019 agitation Methods 0.000 claims 2
- 230000036506 anxiety Effects 0.000 claims 2
- 230000036528 appetite Effects 0.000 claims 2
- 235000019789 appetite Nutrition 0.000 claims 2
- 230000006399 behavior Effects 0.000 claims 2
- 208000013404 behavioral symptom Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 208000019116 sleep disease Diseases 0.000 claims 2
- 208000022925 sleep disturbance Diseases 0.000 claims 2
- 208000028017 Psychotic disease Diseases 0.000 claims 1
- 210000001652 frontal lobe Anatomy 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000002792 vascular Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161520031P | 2011-06-03 | 2011-06-03 | |
| US61/520,031 | 2011-06-03 | ||
| US201161541333P | 2011-09-30 | 2011-09-30 | |
| US61/541,333 | 2011-09-30 | ||
| US201261618680P | 2012-03-31 | 2012-03-31 | |
| US61/618,680 | 2012-03-31 | ||
| PCT/US2012/040789 WO2012173808A1 (en) | 2011-06-03 | 2012-06-04 | Scyllo-inositol for the treatment of behavioral and psychiatric disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2013154699A true RU2013154699A (ru) | 2015-07-20 |
Family
ID=46298680
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2013154699/15A RU2013154699A (ru) | 2011-06-03 | 2012-06-04 | Сцилло-инозитол для применения в лечении поведенческих и психических расстройств |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20140243422A1 (enExample) |
| EP (1) | EP2714050A1 (enExample) |
| JP (1) | JP2014515408A (enExample) |
| KR (1) | KR20140041670A (enExample) |
| CN (1) | CN103906520A (enExample) |
| AU (1) | AU2012271068A1 (enExample) |
| BR (1) | BR112013031117A8 (enExample) |
| CA (1) | CA2837926A1 (enExample) |
| IL (1) | IL229658A0 (enExample) |
| RU (1) | RU2013154699A (enExample) |
| WO (1) | WO2012173808A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7521481B2 (en) | 2003-02-27 | 2009-04-21 | Mclaurin Joanne | Methods of preventing, treating and diagnosing disorders of protein aggregation |
| WO2014110277A1 (en) * | 2013-01-09 | 2014-07-17 | Elan Pharmaceuticals, Inc. | Methods of treating developmental and personality disorders |
| US11191735B2 (en) | 2015-03-13 | 2021-12-07 | Nutrition 21, Llc | Arginine silicate for periodontal disease |
| ES2797688T3 (es) * | 2015-06-30 | 2020-12-03 | Nutrition 21 Llc | Arginina silicato inositol para mejorar la función cognitiva |
| WO2017029353A1 (en) * | 2015-08-20 | 2017-02-23 | Transition Therapeutics Ireland Limited | Treatment of behaviors in dementia patients |
| US20170135969A1 (en) | 2015-11-12 | 2017-05-18 | Jds Therapeutics, Llc | Topical arginine-silicate-inositol for wound healing |
| GB2568849B (en) | 2016-09-01 | 2022-08-10 | Nutrition 21 Llc | Magnesium biotinate compositions and methods of use |
| JP2022515314A (ja) | 2018-11-02 | 2022-02-18 | ニュートリション・２１，エルエルシー | イノシトール安定化アルギニンケイ酸塩複合体及びイノシトールを含有するビデオゲームプレーヤーの認知機能を改善するための組成物 |
| AU2020398082A1 (en) * | 2019-12-02 | 2022-06-16 | Suven Life Sciences Limited | Treating behavioral and psychological symptoms in dementia patients |
| JP2023510082A (ja) * | 2019-12-02 | 2023-03-13 | スヴェン・ライフ・サイエンシーズ・リミテッド | 認知症患者における行動・心理症状を治療するための方法 |
| GB2613672A (en) | 2019-12-16 | 2023-06-14 | Nutrition 21 Llc | Methods of production of aginine-silicate complexes |
| JP2025530190A (ja) * | 2022-09-07 | 2025-09-11 | エアジェン ファーマ リミテッド | アルツハイマー病治療のための免疫療法薬とｓｃｙｌｌｏ－イノシトールとの組み合わせ |
| CN115998724B (zh) * | 2023-03-28 | 2023-06-16 | 中国人民解放军军事科学院军事医学研究院 | 布洛芬在抗幻觉作用药物中的新用途 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7521481B2 (en) * | 2003-02-27 | 2009-04-21 | Mclaurin Joanne | Methods of preventing, treating and diagnosing disorders of protein aggregation |
| IL156203A0 (en) * | 2003-05-29 | 2003-12-23 | Yissum Res Dev Co | Use of 2,2,3,3, tetramethylcyclopropane carboxylic acid derivatives for treating psychiatric disorders |
| EP2298870A1 (en) | 2003-10-14 | 2011-03-23 | Hokko Chemical Industry Co., Ltd. | Method for producing scyllo-inositol |
| CN103054837A (zh) * | 2006-03-09 | 2013-04-24 | 瓦拉塔药品公司 | 用于治疗蛋白积聚病症的环己烷多元醇制剂 |
| ZA200807993B (en) * | 2006-03-09 | 2010-02-24 | Waratah Pharmaceuticals Inc | A cyclohexane polyalcohol formulation for treatment of disorders of protein aggregation |
| CA2789928C (en) | 2010-02-15 | 2020-03-10 | Abbvie Inc. | Process for the preparation of scyllo-inositol |
| US20150306043A1 (en) * | 2012-09-28 | 2015-10-29 | Transition Therapeutics Ireland Limited | Combination treatments for bipolar disorders |
-
2012
- 2012-06-04 KR KR1020147000006A patent/KR20140041670A/ko not_active Withdrawn
- 2012-06-04 RU RU2013154699/15A patent/RU2013154699A/ru not_active Application Discontinuation
- 2012-06-04 WO PCT/US2012/040789 patent/WO2012173808A1/en not_active Ceased
- 2012-06-04 US US14/123,581 patent/US20140243422A1/en not_active Abandoned
- 2012-06-04 CN CN201280037339.8A patent/CN103906520A/zh active Pending
- 2012-06-04 AU AU2012271068A patent/AU2012271068A1/en not_active Abandoned
- 2012-06-04 CA CA2837926A patent/CA2837926A1/en not_active Abandoned
- 2012-06-04 EP EP12727719.2A patent/EP2714050A1/en not_active Withdrawn
- 2012-06-04 BR BR112013031117A patent/BR112013031117A8/pt not_active IP Right Cessation
- 2012-06-04 JP JP2014513795A patent/JP2014515408A/ja active Pending
-
2013
- 2013-11-27 IL IL229658A patent/IL229658A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112013031117A2 (pt) | 2018-06-19 |
| CN103906520A (zh) | 2014-07-02 |
| AU2012271068A1 (en) | 2013-12-19 |
| IL229658A0 (en) | 2014-01-30 |
| WO2012173808A1 (en) | 2012-12-20 |
| BR112013031117A8 (pt) | 2018-08-14 |
| JP2014515408A (ja) | 2014-06-30 |
| KR20140041670A (ko) | 2014-04-04 |
| EP2714050A1 (en) | 2014-04-09 |
| CA2837926A1 (en) | 2012-12-20 |
| US20140243422A1 (en) | 2014-08-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2013154699A (ru) | Сцилло-инозитол для применения в лечении поведенческих и психических расстройств | |
| US11207290B2 (en) | Combinations of cannabinoids and N-acylethanolamines | |
| CN107249567B (zh) | 利鲁唑的舌下给药 | |
| Slowik et al. | Brain inflammasomes in stroke and depressive disorders: regulation by oestrogen | |
| HK1199726A1 (en) | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
| MY166890A (en) | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
| RU2017119222A (ru) | Нейро-аттенуирующие кетаминовые и норкетаминовые соединения, их производные и способы их получения | |
| PH12012501480A1 (en) | Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
| HK1198619A1 (en) | Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
| JP2017510607A5 (enExample) | ||
| JP2017526693A5 (enExample) | ||
| JP2016505050A5 (enExample) | ||
| Guo et al. | Neuroglia and immune cells play different roles in neuroinflammation and neuroimmune response in post-stroke neural injury and repair | |
| CN105209044B (zh) | 用于疼痛病症的治疗性米氮平组合物 | |
| WO2013170711A1 (zh) | 一种用于镇痛的药物组合产品 | |
| CN102793708A (zh) | 天麻素与阿魏酸配伍在制备防治老年性痴呆药物中的应用 | |
| CN104224808A (zh) | 米诺环素用于妊娠期间应激所致的后代神经精神损伤的保护作用 | |
| JP5963791B2 (ja) | 月経前症候群に付随する症状及び月経前不快気分障害を緩和するのに使用される組成物 | |
| CN104703586A (zh) | 1-金刚烷乙氧基-3-吗啉基-2-丙醇或其药学上可接受的盐的药物组合物用于治疗脑血管病变和中枢神经系统中的神经退行性疾病 | |
| CN101884640B (zh) | 谷维素的用途 | |
| Altunova et al. | The Capgras syndrome: a case report | |
| US20190038624A1 (en) | Use of abelson tyrosine kinase inhibitor in treatment of multiple system atrophy | |
| Chetiwal et al. | METRONIDAZOLE CAUSING DISTAL SYMMETRICAL PERIPHERAL NEUROPATHY. | |
| MD3425G2 (ro) | Metodă de profilaxie şi tratament al patologiilor sistemului nervos la copii | |
| Best | How Long Until It Works |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20160927 |